First-in-Human Phase I Study of Iadademstat (ORY-1001): A First-in-Class Lysine-Specific Histone Demethylase 1A Inhibitor, in Relapsed or Refractory Acute Myeloid Leukemia

Autor: Salamero, Olga, Montesinos, Pau, Willekens, Christophe, Pérez-Simón, José Antonio, Pigneux, Arnaud, Récher, Christian, Popat, Rakesh, Carpio Segura, Cecilia del Carmen, Molinero, César, Mascaró, Cristina, Vila, Joaquim, Arévalo, M. Isabel, Maes, Tamara, Buesa, Carlos, Bosch José, Francesc Xavier, The University of Manchester, Universitat Autònoma de Barcelona

Publikováno v: Scientia
Dipòsit Digital de Documents de la UAB
Universitat Autònoma de Barcelona
Journal of Clinical Oncology
Digital.CSIC. Repositorio Institucional del CSIC
instname
JOURNAL OF CLINICAL ONCOLOGY
r-IIS La Fe. Repositorio Institucional de Producción Científica del Instituto de Investigación Sanitaria La Fe

[Purpose] Iadademstat is a novel, highly potent, and selective inhibitor of LSD1 (KDM1A), with preclinical in vitro and in vivo antileukemic activity. This study aimed to determine safety and tolerability of iadademstat as monotherapy in patients wit

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::aef4e440cd2f7ff566f31eee883fc8ef
https://hdl.handle.net/11351/6309

Thermal Hyperalgesia and Light Touch Allodynia After Intradermal Mycobacterium butyricum Administration in Rat.

Autor: Arévalo, M. Isabel, Escribano, Elvira, Calpena, Ana, Domenech, Josep, Querlt, Josep

Publikováno v: Inflammation; Oct2003, Vol. 27 Issue 5, p293-299, 7p

First-in-Human Phase I Study of Iadademstat (ORY-1001): A First-in-Class Lysine-Specific Histone Demethylase 1A Inhibitor, in Relapsed or Refractory Acute Myeloid Leukemia.

Autor: Salamero O; Hospital Vall d'Hebron, Vall D'Hebron Institute of Oncology, Departament de Medicina, Universitat Autònoma de Barcelona, UAB, Barcelona, Spain., Montesinos P; Hospital Universitari I Politécnic La Fe, València, Spain.; Centro de Investigación Biomédica en Red de Cáncer, Instituto Carlos III, Madrid, Spain., Willekens C; Institut Gustave Roussy, Villejuif Cedex, France., Pérez-Simón JA; Hospital Universitario Virgen del Rocío, Sevilla, Spain.; Instituto de Biomedicina de Sevilla (Insitituto de Biomedicina De Sevilla/Consejo Superior De Investigaciones Científicas/Centro de Investigación Biomédica en Red de Cáncer), Universidad de Sevilla, Sevilla, Spain., Pigneux A; Centre Hospitalier Universitaire CHU Bordeaux, Hôpital du Haut Lévêque, Pessac, France., Récher C; Hospitalier Universitaire de Toulouse, Institut Universitaire du Cancer de Toulouse Oncopole, Université Toulouse III Paul Sabatier, Toulouse, France., Popat R; National Institute for Health Research UCLH Clinical Research Facility, University College London Hospitals NHS Foundation Trust, London, United Kingdom., Carpio C; Hospital Vall d'Hebron, Vall D'Hebron Institute of Oncology, Departament de Medicina, Universitat Autònoma de Barcelona, UAB, Barcelona, Spain., Molinero C; Oryzon Genomics, Barcelona, Spain., Mascaró C; Oryzon Genomics, Barcelona, Spain., Vila J; Oryzon Genomics, Barcelona, Spain., Arévalo MI; Oryzon Genomics, Barcelona, Spain., Maes T; Oryzon Genomics, Barcelona, Spain., Buesa C; Oryzon Genomics, Barcelona, Spain., Bosch F; Hospital Vall d'Hebron, Vall D'Hebron Institute of Oncology, Departament de Medicina, Universitat Autònoma de Barcelona, UAB, Barcelona, Spain., Somervaille TCP; The Christie NHS Foundation Trust, Manchester, United Kingdom.; Cancer Research UK Manchester Institute, The University of Manchester, Manchester, United Kingdom.

Publikováno v: Journal of clinical oncology : official journal of the American Society of Clinical Oncology [J Clin Oncol] 2020 Dec 20; Vol. 38 (36), pp. 4260-4273. Date of Electronic Publication: 2020 Oct 14.